UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Read More Share:linkedin| twitter| email

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Sep

27

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Read More Share:linkedin| twitter| email

Aug

16

UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")

Read More Share:linkedin| twitter| email

May

23

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Apr

10

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Apr

04

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Read More Share:linkedin| twitter| email

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Read More Share:linkedin| twitter| email

Oct

13

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Read More Share:linkedin| twitter| email

Oct

13

Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)